Would you volunteer to be deliberately infected with COVID-19? It's a question some people are seriously considering. In an effort to speed up the development of a vaccine, 1 Day Sooner is asking volunteers to sign up for human challenge trials that will expose them to the virus in an effort to study the disease and develop a cure.
Josh Morrison, the co-founder of 1 Day Sooner, told Cheddar Wednesday that these human challenges have been used to study other diseases in the past, including malaria, typhoid, and cholera.
"The drug Tamiflu, for example, was developed with challenge trials, as well as the malaria vaccine RTS,S that's being deployed in Africa right now," he said. "You can find out much more quickly whether a vaccine might work, than a traditional trial which might have thousands or even tens of thousands of volunteers."
The National Institutes of Health and the World Health Organization have shown interest in the human challenge trials, according to Morrison. The WHO recently published an ethics report to which the 1 Day Sooner team offered suggestions, though they were not accepted for the publication.
Morrison said that there has been growing interest in the trials, adding, "It's not universal acclaim or an immediate 'we need challenge trials right away from every possible corner,' but the message today is immensely different, immensely more positive than what the public message was a month ago."
He acknowledged that the risk of injecting people with COVID-19 could be deadly, but he said he believes that the potential value of finding a vaccine from these challenges is worth it.
"If you look at the risks of getting COVID-19 for the young, healthy group that would participate in challenge trials, they're roughly on a par with childbirth or with kidney donation. So, again, significant risk and we're not understating that, but these are risks that we commonly allow people to accept normally, and given the tremendous possible value we think it's worth accepting them in this case," the 1 Day Sooner co-founder said.
2021 was an exciting year for space innovations, but 2022 could hold even more in store. Cheddar took a deep dive into the space mission on tap for the year ahead.
The United States purchased over 600,000 doses of a monoclonal antibody treatment from Glaxosmithkline and Vir Biotechnology, bringing the total worldwide doses purchased to 1.7 million. This comes as the country attempts to ramp up treatment options as cases of the omicron variant continue to surge. Dr. Asha Shah, Director of Infectious Diseases at Stamford Health joined Cheddar's Opening Bell to discuss.
As the pandemic slammed the brakes on the nation's economy in 2020, America's greenhouse gas emissions reached their lowest levels in at least three decades. However, as the world, and the economy re-opened, 2021 told a much different story as emissions surged. Biden's flagship 'Build Back Better' act involves billions in spending on electric cars and renewables, in an effort to cut U.S. emissions, experts are still skeptical that the nation will meet the current 2030 target. Andrew Dessler, professor of atmospheric sciences at Texas A&M University, joins Cheddar News.
Amid the omicron surge, a new debate has emerged about whether or not throat swabs are more effective than nasal swabs for COVID testing. Dr. William Schaffner, MD, professor of infectious diseases, Vanderbilt Medical Center, sat down with Cheddar's News Wrap to weigh in on the dispute. "Should there be a change? You've got to do the studies, show that in the field [a throat swab] works as well or better than the nasal specimen," he said. "Let's not do it off our hips, as we say."
Virginia Governor Ralph Northam is declaring a state of emergency after Monday's winter storm left hundreds of drivers stranded on the interstate for more than 24 hours.
The snow also knocked out power for many residents, with more than 100,000 outages remaining days later.
Michael Wehner, a climate scientist at Lawrence Berkeley national laboratory, discusses recent weather disasters.
As the need for COVID-19 testing increases, so does the price of the tests themselves. An agreement with The White House and several major companies to sell the tests at a lower cost has now expired, sending prices up as retailers struggle to keep kits on shelves. Dr. Thomas McGinn, executive VP of physician enterprise at Common Spirit Health, joins Cheddar News to discuss.
A new report shows 2021 saw a surge in U.S. greenhouse gas emissions, indicating that the country remains far off track from meeting President Biden's climate change targets. Biden previously pledged to cut the nation's emissions in half by 2030, and now experts warn that immediate action must be taken in order to get the nation back on track. Zeke Hausfather, director of climate and energy at The Breakthrough Institute on U.S. Emissions and Global Temperatures, joins Cheddar News to discuss.
Electric vehicles are quickly becoming an accessible way for consumers to slash emissions as legacy automakers begin to electrify their fleets and world leaders including President Joe Biden push for broad EV adoption. But consumers have concerns about EV range, the availability of charging stations, and more. What if it were both helpful to consumers — and feasible from a climate change standpoint — to keep hybrid models that run on gas on the market? Gill Pratt, CEO of the Toyota Research Institute & Toyota Motor Corporation's Chief Scientist joins Cheddar Climate to discuss his team's research about 'carbon return on investment,' how Toyota is electrifying its fleet, and more.
According to a recent analysis compiled by The Washington Post, more than four in 10 Americans lived in areas hit by climate-related disasters in 2021. Jonathan Porter, Chief Meteorologist at AccuWeather, joined Cheddar Climate to discuss what this means and what can be done to prevent severe weather events from becoming even worse.
It's a painfully cold week across a large portion of the U.S. with more than 185 million Americans experiencing below-freezing temperatures on Monday and 10 million of them dealing with dangerous sub-zero temps.
